A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Axitinib (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 07 May 2019 Planned End Date changed from 18 Jun 2023 to 9 Jan 2024.
- 07 May 2019 Planned primary completion date changed from 18 Jun 2023 to 9 Jan 2024.
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.